192 related articles for article (PubMed ID: 9469582)
1. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor.
Bisgaier CL; Essenburg AD; Barnett BC; Auerbach BJ; Haubenwallner S; Leff T; White AD; Creger P; Pape ME; Rea TJ; Newton RS
J Lipid Res; 1998 Jan; 39(1):17-30. PubMed ID: 9469582
[TBL] [Abstract][Full Text] [Related]
2. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Haubenwallner S; Essenburg AD; Barnett BC; Pape ME; DeMattos RB; Krause BR; Minton LL; Auerbach BJ; Newton RS; Leff T
J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.
Dallongeville J; Baugé E; Tailleux A; Peters JM; Gonzalez FJ; Fruchart JC; Staels B
J Biol Chem; 2001 Feb; 276(7):4634-9. PubMed ID: 11050100
[TBL] [Abstract][Full Text] [Related]
4. MDL 29311, a phenolic antioxidant, interferes with the interaction of apoC with VLDL: a possible explanation for its triglyceride-lowering effect.
Sheetz MJ
J Lipid Res; 1995 Dec; 36(12):2609-21. PubMed ID: 8847487
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine.
Hasler-Rapacz J; Kempen HJ; Princen HM; Kudchodkar BJ; Lacko A; Rapacz J
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):137-43. PubMed ID: 8548414
[TBL] [Abstract][Full Text] [Related]
6. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF
Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106
[TBL] [Abstract][Full Text] [Related]
7. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
[No Abstract] [Full Text] [Related]
8. Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats.
Krause BR; Barnett BC; Essenburg AD; Kieft KA; Auerbach BJ; Bousley R; Stanfield R; Newton RS; Bisgaier CL
Atherosclerosis; 1996 Nov; 127(1):91-101. PubMed ID: 9006809
[TBL] [Abstract][Full Text] [Related]
9. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
Hughes TA; Stentz F; Gettys T; Smith SR
Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.
Krause BR; Newton RS
J Lipid Res; 1985 Aug; 26(8):940-9. PubMed ID: 3862732
[TBL] [Abstract][Full Text] [Related]
11. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan DC; Watts GF; Nguyen MN; Barrett PH
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
[TBL] [Abstract][Full Text] [Related]
12. Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets.
Himber J; Missano B; Rudling M; Hennes U; Kempen HJ
J Lipid Res; 1995 Jul; 36(7):1567-85. PubMed ID: 7595080
[TBL] [Abstract][Full Text] [Related]
13. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
15. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms.
Srivastava RA
Mol Cell Biochem; 1996 Feb; 155(2):153-62. PubMed ID: 8700160
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH
Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883
[TBL] [Abstract][Full Text] [Related]
18. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.
Sacks FM; Alaupovic P; Moye LA; Cole TG; Sussex B; Stampfer MJ; Pfeffer MA; Braunwald E
Circulation; 2000 Oct; 102(16):1886-92. PubMed ID: 11034934
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: relationship to very low density lipoprotein composition.
Elam MB; von Wronski MA; Cagen L; Thorngate F; Kumar P; Heimberg M; Wilcox HG
Lipids; 1999 Aug; 34(8):809-16. PubMed ID: 10529091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
